Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Autologous hematopoietic stem cell transplantation did not improve outcomes for patients with mantle cell lymphoma and undetectable minimal residual disease.

The following is a summary of “Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: ...

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

assam lottery result Pfizer's rituximab biosimilar approved by EU This is not the first time that Sanofi has been involved in kickback scandals Hanyu Pharmaceuticals' "Liraglutide Injection" is listed ...

INR:8199. what is the largest casino in maryland AstraZeneca announces subgroup analysis data of Brilinta Phase IV clinical ...

Ibrutinib: The best-selling tinib drug in the world in 2018 and the first BTK inhibitor to be launched Henlius's new ...

INR:6606. satta king Rituxan faces another competitor: the second domestic rituximab is launched Found immune cells targeting tumors in 1 day! Wu Peng's team brings ne ...

INR:2270. betting websites with sign up bonus CDE: Drugs that meet two conditions can apply for marketing approval during ...